Prevalence of NAFLD in T1DM Patients

N/ARecruitingNCT06445361

Ziekenhuis Oost-Limburg138 enrolled

Overview

To determine the prevalence of NAFLD in T1DM patients.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

138

Conditions

NAFLD Type 1 Diabetes Fatty Liver, Nonalcoholic

Interventions

FibroScanDIAGNOSTIC_TEST

Performance of a FibroScan measurement to determine steatosis and fibrosis.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * T1DM * ≥ 18 years of age * Written informed consent obtained Exclusion Criteria: * Excessive alcohol use * Exclusion of other causes of liver disease and secondary causes of liver steatosis

Locations (1)

Ziekenhuis Oost-Limburg

Genk, Limburg, Belgium

RECRUITING

Outcomes

Primary Outcomes

Prevalence of NAFLD in T1DM

To determine the prevalence of steatosis in a cohort of T1DM patients followed at the Departments of Endocrinology in ZOL by means of the FibroScan® device with controlled attenuation parameter (CAP) measurements.

Time frame: During the intervention

Prevalence of fibrosis in T1DM

To determine the prevalence of fibrosis in a cohort of T1DM patients followed at the Departments of Endocrinology in ZOL by means of the FibroScan® device with vibration controlled attenuation parameter (VCTE) measurements.

Time frame: During the intervention

Central Contacts

Leen Heyens, MsC

CONTACT

089 21 20 55 nafldstudie@zol.be

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.